梅斯心血管疾病进展(003期)

2021-06-04 K.K MedSci原创

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最近一期的神经进展。enjoy~

canohealth

编者按:梅斯医学将定期进行汇总,帮助大家概览血管领域最新进展。下面是呈现给大家的最近一期的神经进展。enjoy~

上一期见:梅斯心血管疾病进展(002期)

1. 更长和更频繁的日间小睡或可导致未来心衰风险升高

夜间睡眠中断与心力衰竭 (HF) 相关。然而,白天小睡(老年人常见的睡眠行为)与HF之间的关系仍不清楚。近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员试图调查客观评估的白天小睡与随访期间发生HF风险之间的关联。研究人员分析了1140名老年人(年龄为80.7±7.4 [SD] 岁;女性为867人[76.1%]),他们在基线时没有HF并且每年进行随访,长达14年。在基线时,研究人员记录了受试者运动水平,共10天。

86名参与者发生了HF,平均发病时间为5.7年(SD为3.4;范围为1-14)。午睡时间超过 44.4 分钟(即每日午睡时间的中位数)的参与者发生HF的风险比午睡时间<44.4分钟的参与者高出1.73倍。与小睡次数<1.7次/天的参与者相比,小睡次数>1.7次/天(即每日小睡频率的中位数)的参与者显示HF风险增加了2.20倍。在调整协变量(包括夜间睡眠、合并症和心血管疾病/危险因素)后,这些关联仍然存在。

由此可见,更长和更频繁的日间小睡可导致未来HF风险升高

详情参考:JAHA:老年人白天小睡与心衰的关系

2. 单基因突变可能导致我们许多人多长30斤脂肪!

最新研究发现,大约每340人中就有1人可能携带MC4R的单基因突变。携带这些基因突变的人从幼儿期起,就拥有更大的体重,到18岁时,他们的平均体重高出约17公斤,其中过量的体重大部分是脂肪。

这项研究由英国剑桥大学MRC代谢疾病组的Stephen O’Rahilly和布里斯托大学MRC综合流行病学组的Nicholas J. Timpson领导,于5月27日发表在《自然医学》杂志上。

详情参考:Nat Med:单基因突变可能导致我们许多人多长30斤脂肪!

3.平均动脉压和脉压与年龄的协同作用增加了年龄对白质高信号和扩散指数的影响。

近日,心血管权威杂志Hypertension上发表了一篇研究文章,这项研究是对来自22个英国中心的基于社区成人的英国生物样本库队列研究进行的横断面分析。

在37041名年龄在45到82岁的参与者(53%为女性)中,单变量分析表明,BP升高都与更大的WMH体积扩散指数和白质损伤相关,对于PP具有更大的效应(WMH的标准化效应大小:平均动脉BP:0.182 (95%CIs为0.170-0.193);PP:0.285 [95%CIs为0.274-0.296])。在多变量分析中,与平均动脉压之间的相关性相似,但与PP的相关性有所减弱,反映了与年龄和危险因素的协方差(WMH的标准化效应大小:平均动脉BP:0.106 [95%CI为0.095-0.117];PP:0.011 [95%CI为-0.001至0.023])。

由此可见,PP与年龄的协同作用增加了年龄对WMH和扩散指数的影响。尽管PP加重了年龄与白质损伤的关系,但宏观和微观白质损伤与高血压的搏动性和稳定性参数具有相似的相关性

详情参考:Hypertension:脑白质高信号和微结构损伤的血压决定参数

4. 高抑郁症状与肾功能快速下降的高风险明显相关

近日,中国南方医科大学南方医院秦献辉教授领导的团队在一项针对肾功能正常的成年人的研究中发现,抑郁症状和肾功能快速下降之间存在联系。该研究发表在《美国肾脏病学会临床杂志》CJASN上。

研究人员从中国健康和退休纵向研究中共招募了4763名基线时eGFR≥60ml/min/1.73m2的参与者。基线抑郁症状是用流行病学研究中心的十项抑郁量表来确定的,大于或等于10分的分值为高抑郁症状。主要结果是肾功能的快速下降,定义为每1.73平方米的eGFR年化下降≥5毫升/分钟。次要结果被定义为年化eGFR下降≥5毫升/分钟/1.73平方米,并在退出时达到<60毫升/分钟/1.73平方米的水平。

研究表明,在肾功能正常的中国成年人中,高抑郁症状与肾功能快速下降的高风险明显相关。

详情参考:CJASN:抑郁症将提高肾功能下降风险

5. 征收饮料税能使年轻人含糖饮料的摄入量大幅减少

大量研究已经证实,过量的添加糖,特别是含糖饮料的添加糖,是血管疾病和2型糖尿病等心血管代谢疾病的主要危险因素。为了预防和降低肥胖症和糖尿病患者的患病率,南非在2018年4月实施了一项基于糖含量的税收,称为健康促进税,这是第一批基于含糖饮料(SSB)税收之一。这为了估计SSB量在征税1年后的变化,来自北卡罗来纳大学全球公共卫生学院营养系的专家开展了相关研究。结果发表在《公共科学图书馆》子刊PLOS Medicine杂志上。

研究人员在南非对18-39岁的成年人进行重复横断面调查,收集了单日24小时饮食回顾。2018年2-3月(税前,n = 2459)和2019年2-3月(税后,n = 2489)采用上门抽样的方式招募了参与者。研究人员还开发了税前和税后南非饮料的特定时间食物成分表(FCTs),并与饮食回顾联系起来。

在未征税的饮料中,糖的摄入量增加了5.3克/人/天,能量摄入增加了29千卡/人/天。在所有饮料中,糖的摄入量明显减少3.7克/人/天。行为改变使能量摄入减少了24%,糖减少了22%,体积减少了23%,而重新配制使被征税饮料的能量减少了8%,糖减少了9%,体积减少了14%。

综上,征收饮料税能使年轻人含糖饮料的摄入量大幅减少。

详情参考:PLOS MED:含糖饮料税能为年轻人减轻“甜蜜的负担”吗?

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
    2021-11-09 湘雅科教

    已拜读,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
    2021-06-15 12192b1am98暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
    2021-06-06 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
    2021-06-04 weigq

    好文!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1068443, encodeId=a1a3106844301, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:21:00 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907751, encodeId=192b190e751c5, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Feb 03 22:51:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973882, encodeId=bac19e388283, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Tue Jun 15 21:54:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277214, encodeId=31ec12e7214cf, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498889, encodeId=96981498889ee, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Jun 06 04:51:37 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970887, encodeId=92459e0887d8, content=好文!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Fri Jun 04 15:14:41 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970880, encodeId=745c9e0880a4, content=好的app, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/a4eea2680d3647f7ac67f6f9457c2a21/995b2f39c1b74311b0d0b89bb40c7aa0.jpg, createdBy=dde05496707, createdName=ms9000001950324973, createdTime=Fri Jun 04 14:53:13 CST 2021, time=2021-06-04, status=1, ipAttribution=)]
    2021-06-04 ms9000001950324973

    好的app

    0

相关资讯

BMJ子刊:注意!一线医护人员多睡1小时,感染COVID-19的风险降低12%!

最新的研究发现,新冠抗疫期间,长期高压高风险的工作状态导致的失眠、倦怠,会反之进一步增加医护人员受感染的风险。因此,有必要采取措施,更合理地评估医护人员工作压力,优化轮休制度,保证职业安全。

哈佛大学84万人的研究发现:晚上11点前睡觉,抑郁风险降低40%!

早上可以喝杯咖啡。方便的话,步行或骑自行车上班,晚上将电子产品调暗

Sleep:良好睡眠有助于视力!近视人群睡眠质量或更差

高度近视可能还会增加白内障、青光眼、视网膜脱离和近视眼黄斑变性等眼部病变的风险

Nutrients:营养干预可提高睡眠紊乱患者的睡眠质量

紊乱的睡眠可能对身体健康、认知能力、新陈代谢和总体健康产生负面影响。营养干预是提高睡眠质量和数量的一种潜在的非药物手段。近日,研究人员进行一项新的研究,旨在1)确定一套最佳的营养成分,(2)利用多导睡

Neurology: 20万大数据研究: 脑外伤后,多数人的长期睡眠质量堪忧

20万大数据研究 脑外伤后,多数人的长期睡眠质量堪忧